Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.43 |
| ▸ | HTR2C | P28335 | 5/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906137 | 0.86 | HTR1A (0.39) | HTR2AHTR2CHRH1HTR1ALMNA | |
| SCHEMBL6906280 | 0.84 | HTR1A (0.61) | HTR2AHTR2CHTR1ASMN1; SMN2DRD2 | |
| SCHEMBL6782174 | 0.81 | HTR2A (0.51) | HTR2AHTR2CHRH1HTR1ALMNA | |
| SCHEMBL11107203 | 0.78 | ADRA2A (0.55) | HTR2AHTR2CHRH1HTR1ALMNA | |
| Hydrochloric Acid SCHEMBL11104894 | 0.77 | HTR2C (0.54) | HTR2AHTR2CHRH1HTR1ALMNA | |
| SCHEMBL6321111 | 0.77 | HTR2C (0.45) | HTR2AHTR2CHRH1HTR1ALMNA | |
| SCHEMBL6990695 | 0.76 | DRD2 (0.48) | HTR2AHTR2CHRH1LMNASMN1; SMN2 | |
| SCHEMBL7038063 | 0.75 | HTR2A (0.42) | HTR2AHTR2CHRH1HTR1ALMNA | |
| SCHEMBL6796362 | 0.75 | HTR1A (0.49) | HTR1A | |
| SCHEMBL11107814 | 0.73 | DRD2 (0.56) | HTR2AHTR2CLMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800642-B2 | SUCH AS BENZYL-(-7,8-DIHYDRO-2,6,9-TRIOXA-3-AZA-CYCLOPENTA(A)NAPHTHALEN-8-YLMETHYL) -AMINE; FOR TREATMENT OF DRUG DEPENDENCE/ADDICTION, BIPOLAR DISORDER, PARKINSON'S DISEASE, LEVODOPA INDUCED PSYCHOSES OR DYSKINESIAS | WYETH | 2004-10-05 | — | — | US | claimed |
| US-20020198217-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-2,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | WYETH (US) | 2002-12-26 | — | — | US | claimed |
| US-6800642-B2 | SUCH AS BENZYL-(-7,8-DIHYDRO-2,6,9-TRIOXA-3-AZA-CYCLOPENTA(A)NAPHTHALEN-8-YLMETHYL) -AMINE; FOR TREATMENT OF DRUG DEPENDENCE/ADDICTION, BIPOLAR DISORDER, PARKINSON'S DISEASE, LEVODOPA INDUCED PSYCHOSES OR DYSKINESIAS | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20020198217-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-2,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | WYETH (US) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198217-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-2,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | SNCA, SYNJ2, PARK7 | HTR2A 46/4885HTR2C 36/4885HRH1 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.